Skip to main content
Premium Trial:

Request an Annual Quote

Colds and Cancer

Premium

There is no cure for the common cold, but for cancer patients, that may be a good thing. In a new study in Science Translational Medicine, researchers from Leeds University and the Institute of Cancer Research in the UK describe a method that uses the common cold virus to kill tumors and trigger an anti-cancer immune response in patients, reports Reuters' Kate Kelland. The team conducted the study on 10 patients with advanced bowel cancer with liver metastases who were due to have surgery. They gave the patients up to five doses of an experimental reovirus vaccine therapy and later confirmed in tissue samples that the virus had targeted and become active in the cancerous tissue while leaving normal liver tissue alone, Kelland says. Not only did the virus attack cancer cells, it also caused the body's immune system to kill off any remaining cancer cells.

"By hitching a ride on blood cells, the virus was protected from antibodies in the blood stream that might otherwise neutralize its cancer-fighting abilities," she adds. "The findings suggest viral therapies like this, called reovirus, could be injected into the blood stream at routine outpatient appointments — like standard chemotherapy — making them potentially suitable for treating a range of cancers."

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more